Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. The investigational compounds within Qualigen’s family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers.
Company profile
Ticker
QLGN
Exchange
Website
CEO
Andrew Ritter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
RITTER PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Qualigen, Inc. • NanoSynex Ltd. ...
QLGN stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
16 Apr 24
10-K
2023 FY
Annual report
5 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Termination of a Material Definitive Agreement
28 Mar 24
8-K
Entry into a Material Definitive Agreement
27 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Entry into a Material Definitive Agreement
7 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Nov 23
8-K
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
Transcripts
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
57.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 6 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 3.28 bn |
Total shares | 3.63 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Alpha Capital Anstalt | 3.53 mm | $1.86 mm |
Meitav Dash Investments | 27.29 k | $3.21 bn |
BLK Blackrock | 25.84 k | $23.54 mm |
Geode Capital Management | 22.15 k | $20.18 mm |
STT State Street | 10.93 k | $9.96 mm |
HighMark Wealth Management | 8.01 k | $7.30 mm |
Tower Research Capital | 4.61 k | $4.20 mm |
UBS UBS Group AG - Registered Shares | 1.37 k | $1.25 mm |
USB U.S. Bancorp. | 824.00 | $751.00 k |
FMR | 512.00 | $466.00 k |
News
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented At American Association Of Cancer Research 2024 Annual Meeting
10 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
27 Feb 24
Qualigen Therapeutics New Publication Released In The Nature Scientific Reports Journal Titled "Structure–Activity Relationships For The G-Quadruplex-Targeting Experimental Drug QN-302 And Two Analogues Probed With Comparative Transcriptome Profiling And Molecular Modeling"
12 Feb 24